\-\ Texto\\:\\ \ \(0\)\
\-\ physical\\ exam\\ was\\ within\\ normal\\ limits\\ at\\ the\\ time\\ of\\ study\\.\\ \\ no\\ neurological\\ deficits\\ were\\ noted\\,\\ nor\\ were\\ there\\ any\\ residual\\ deficits\\ from\\ the\\ suspected\\ prior\\ event\\ at\\ age\\ 5\\.\ \(0\)\
\-\ hemoglobin\\ electrophoresis\\:\\ \ \(0\)\
\-\ hgs\\ 25\\.6\\ \\%\\,\\ hga2\\ 3\\.2\\%\\,\\ hgf\\ 1\\.7\\ \\%\\,\\ hga\\ 69\\.2\\%\ \(0\)\
\-\ cbc\\:\\ \\ wbc\\ 12\\.0\\,\\ hgb\\ 10\\.0\\,\\ hct\\ 28\\.5\\,\\ plt\\ 303\ \(0\)\
\-\ treatment\\ of\\ moyamoya\\ is\\ directed\\ at\\ the\\ complications\\.\\ \\ if\\ an\\ intracerebral\\ hemorrhage\\ has\\ occurred\\,\\ managment\\ of\\ hypertension\\ is\\ warranted\\.\\ \\ if\\ ischemia\\ has\\ occurred\\,\\ anticoagulation\\ and\\/or\\ antithrombotic\\ therapy\\ should\\ be\\ considered\\.\ \(0\)\
\-\ patients\\ who\\ present\\ for\\ treatment\\ while\\ symptoms\\ are\\ evolving\\ have\\ a\\ better\\ prognosis\\ than\\ those\\ who\\ present\\ with\\ static\\ symptoms\\.\ \(0\)\
\-\ various\\ surgical\\ procedures\\ have\\ been\\ used\\:\\ superficial\\ temporal\\ artery\\â\\€\\“middle\\ cerebral\\ artery\\ \\(sta\\-mca\\)\\ anastomosis\\,\\ encephaloduroarteriosynangiosis\\ \\(edas\\)\\,\\ encephaloduroarteriomyosynangiosis\\ \\(edams\\)\\,\\ pial\\ synangiosis\\,\\ and\\ omental\\ transplantation\\ to\\ the\\ cns\\.\ \(0\)\
\-\ there\\ is\\ significant\\ vasculopathy\\ compatible\\ with\\ sickle\\ cell\\ disease\\.\\ \\ there\\ is\\ severe\\ narrowing\\ of\\ the\\ cavernous\\ and\\ supraclinoid\\ portions\\ of\\ the\\ left\\ internal\\ carotid\\ artery\\ and\\ narrowing\\ at\\ the\\ origins\\ of\\ the\\ left\\ a1\\ and\\ left\\ m1\\ segments\\ of\\ the\\ internal\\ carotid\\ artery\\.\\ \\ the\\ left\\ middle\\ cerebral\\ artery\\ appears\\ attenuated\\.\\ \\ there\\ is\\ diminished\\ flow\\ identified\\ at\\ and\\ distal\\ to\\ the\\ trifurcation\\ of\\ the\\ left\\ middle\\ cerebral\\ artery\\.\\ \\ \ \(0\)\
\-\ moyamoya\\ collateral\\ vessels\\ are\\ again\\ identified\\ in\\ the\\ left\\ basal\\ ganglia\\ region\\ and\\ also\\ at\\ the\\ region\\ of\\ the\\ bifurcation\\ of\\ the\\ left\\ internal\\ carotid\\ artery\\ and\\ the\\ right\\ cerebral\\ peduncle\\ region\\.\\ \ \(0\)\
\-\ the\\ anterior\\ and\\ posterior\\ branches\\ of\\ the\\ middle\\ menigeal\\ arteries\\ appear\\ more\\ prominent\\,\\ reflecting\\ collateral\\ supply\\ from\\ the\\ external\\ carotid\\ circulation\\.\ \(0\)\
\-\ moyamoya\\ disease\\ secondary\\ to\\ sickle\\ cell\\ disease\ \(0\)\
\-\ \\â\\€\\¢\\ anterior\\ circulation\\ stroke\ \(1\)\
\-\ \\â\\€\\¢\\ basilar\\ artery\\ thrombosis\ \(1\)\
\-\ \\â\\€\\¢\\ blood\\ dyscrasias\ \(1\)\
\-\ \\â\\€\\¢\\ moya\\-moya\\ disease\ \(0\)\
\-\ 19\\ year\\ old\\ with\\ sickle\\ cell\\ disease\\.\\ \\ at\\ 5\\ years\\ of\\ age\\,\\ he\\ presented\\ with\\ dysarthria\\,\\ confusion\\,\\ and\\ mild\\ right\\ hemiparesis\\;\\ and\\,\\ had\\ an\\ apparently\\ normal\\ mri\\ at\\ this\\ time\\.\\ between\\ the\\ ages\\ of\\ 5\\ and\\ 19\\,\\ he\\ has\\ not\\ had\\ any\\ symptomatic\\ vascular\\ events\\.\\ \\ he\\ presents\\ now\\ for\\ follow\\ up\\ and\\ screening\\ exam\\ for\\ cerebrovascular\\ pathology\\.\ \(0\)\
\-\ this\\ patient\\ has\\ significant\\ vasculopathy\\ with\\ some\\ new\\ development\\ of\\ collateralization\\.\\ \\ there\\ is\\ increased\\ signal\\ within\\ the\\ frontal\\ lobes\\ implying\\ low\\ grade\\ chronic\\ ischemia\\.\\ \\ these\\ findings\\ can\\ manifest\\ as\\ problems\\ with\\ executive\\ functioning\\,\\ planning\\ and\\ organizing\\ and\\ can\\ effect\\ activities\\ of\\ daily\\ living\\.\\ \\ in\\ this\\ patient\\ asynangiosis\\ procedure\\ is\\ being\\ considered\\,\\ as\\ well\\ as\\,\\ a\\ diamox\\ challenge\\ scan\\ to\\ fully\\ assess\\ candidacy\\.\\ \\ he\\ has\\ been\\ on\\ chronic\\ blood\\ tranfusions\\ with\\ the\\ hope\\ of\\ preventing\\ further\\ significant\\ cerebrovascular\\ events\\.\ \(0\)\
\-\ of\\ note\\,\\ a\\ study\\ reported\\ in\\ blood\\,\\ 1\\ may\\ 2002\\,\\ noted\\ that\\ \\'chronic\\ transfusions\\ are\\ effective\\ in\\ preventing\\ the\\ recurrance\\ of\\ infarctive\\ strokes\\ in\\ sickle\\ cell\\ disease\\ \\(scd\\)\\.\\ \\ the\\ reasons\\ why\\ some\\ patients\\ develop\\ recurrances\\ while\\ complying\\ with\\ transfusions\\ are\\ unknown\\.\\'\\ \\ this\\ study\\ reported\\ that\\ 41\\%\\ of\\ scd\\ patients\\ had\\ a\\ recurrent\\ cerebrovascular\\ event\\ even\\ with\\ compliant\\ transfusion\\ therapy\\.\\ \\ in\\ addition\\,\\ \\'patients\\ with\\ moyamoya\\ collaterals\\ were\\ found\\ to\\ be\\ at\\ higher\\ risk\\ for\\ recurrent\\ strokes\\ and\\ tias\\ compared\\ with\\ patients\\ without\\ these\\ collaterals\\.\\'\\ \\ the\\ authors\\ mentioned\\ some\\ therapy\\ options\\ which\\ this\\ patient\\ is\\ currently\\ not\\ utilizing\\:\\ \\ hydroxyurea\\ and\\ phlebotomy\\ and\\ bone\\ marrow\\ transplantation\\,\\ all\\ as\\ options\\ to\\ decrease\\ the\\ risk\\ of\\ future\\ cva\\,\\ as\\ well\\ as\\,\\ prevention\\ of\\ worsening\\ neuropsychological\\ complications\\ due\\ to\\ poor\\ perfusion\\.\\ \\ blood\\,\\ 1\\ may\\ 2002\\.\\ volume\\ 99\\.\\ \\ number\\ 9\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ moyamoya\\:\\ 0\\.22936844487439717\ \(0\)\
\-\ the\\:\\ 0\\.21474487467870546\ \(0\)\
\-\ artery\\:\\ 0\\.19804570401985297\ \(0\)\
\-\ of\\:\\ 0\\.16380892799721095\ \(0\)\
\-\ sickle\\:\\ 0\\.1576767517014804\ \(0\)\
\-\ cerebrovascular\\:\\ 0\\.15749596051768386\ \(0\)\
\-\ and\\:\\ 0\\.14825844977993652\ \(0\)\
\-\ at\\:\\ 0\\.13550063208539856\ \(0\)\
\-\ carotid\\:\\ 0\\.1343031764716047\ \(0\)\
\-\ scd\\:\\ 0\\.11780271266543561\ \(0\)\
\-\ middle\\:\\ 0\\.11401285270439306\ \(0\)\
\-\ vasculopathy\\:\\ 0\\.11213623039391382\ \(0\)\
\-\ patients\\:\\ 0\\.11211714355229539\ \(0\)\
\-\ cerebral\\:\\ 0\\.1104614897589622\ \(0\)\
\-\ strokes\\:\\ 0\\.10366532200652785\ \(0\)\
\-\ disease\\:\\ 0\\.10039086626044083\ \(0\)\
\-\ collaterals\\:\\ 0\\.09678283269698268\ \(0\)\
\-\ as\\:\\ 0\\.09607905460098745\ \(0\)\
\-\ transfusions\\:\\ 0\\.09602722896025687\ \(0\)\
\-\ left\\:\\ 0\\.0951798021985454\ \(0\)\
\-\ preventing\\:\\ 0\\.09462853612024451\ \(0\)\
\-\ he\\:\\ 0\\.09441451840006276\ \(0\)\
\-\ events\\:\\ 0\\.0939784065811185\ \(0\)\
\-\ transplantation\\:\\ 0\\.09276239954309512\ \(0\)\
\-\ blood\\:\\ 0\\.09259666077656802\ \(0\)\
\-\ cell\\:\\ 0\\.09120702078217517\ \(0\)\
\-\ has\\:\\ 0\\.0910344278840725\ \(0\)\
\-\ is\\:\\ 0\\.08732744967561049\ \(0\)\
\-\ circulation\\:\\ 0\\.08634031353484752\ \(0\)\
\-\ with\\:\\ 0\\.08585594484377208\ \(0\)\
\-\ internal\\:\\ 0\\.08058986676280339\ \(0\)\
\-\ study\\:\\ 0\\.07975123904309953\ \(0\)\
\-\ event\\:\\ 0\\.07949874743125226\ \(0\)\
\-\ there\\:\\ 0\\.07930084712190086\ \(0\)\
\-\ occurred\\:\\ 0\\.07702609392538325\ \(0\)\
\-\ collateral\\:\\ 0\\.07629038380745545\ \(0\)\
\-\ 2002\\:\\ 0\\.07629038380745545\ \(0\)\
\-\ some\\:\\ 0\\.0752385667367924\ \(0\)\
\-\ options\\:\\ 0\\.07187252297579716\ \(0\)\
\-\ region\\:\\ 0\\.07152734721106706\ \(0\)\
\-\ chronic\\:\\ 0\\.07097926639018076\ \(0\)\
\-\ to\\:\\ 0\\.06975444808884956\ \(0\)\
\-\ ischemia\\:\\ 0\\.06904436974923225\ \(0\)\
\-\ significant\\:\\ 0\\.06904285396991264\ \(0\)\
\-\ therapy\\:\\ 0\\.0687064618208449\ \(0\)\
\-\ deficits\\:\\ 0\\.06852089039233082\ \(0\)\
\-\ this\\:\\ 0\\.06848306533692476\ \(0\)\
\-\ recurrent\\:\\ 0\\.06392174072638221\ \(0\)\
\-\ hgs\\:\\ 0\\.06374481404542248\ \(0\)\
\-\ hga2\\:\\ 0\\.06374481404542248\ \(0\)\
\-\ hgf\\:\\ 0\\.06374481404542248\ \(0\)\
\-\ hga\\:\\ 0\\.06374481404542248\ \(0\)\
\-\ antithrombotic\\:\\ 0\\.06374481404542248\ \(0\)\
\-\ encephaloduroarteriosynangiosis\\:\\ 0\\.06374481404542248\ \(0\)\
\-\ edas\\:\\ 0\\.06374481404542248\ \(0\)\
\-\ encephaloduroarteriomyosynangiosis\\:\\ 0\\.06374481404542248\ \(0\)\
\-\ edams\\:\\ 0\\.06374481404542248\ \(0\)\
\-\ synangiosis\\:\\ 0\\.06374481404542248\ \(0\)\
\-\ menigeal\\:\\ 0\\.06374481404542248\ \(0\)\
\-\ asynangiosis\\:\\ 0\\.06374481404542248\ \(0\)\
\-\ infarctive\\:\\ 0\\.06374481404542248\ \(0\)\
\-\ recurrances\\:\\ 0\\.06374481404542248\ \(0\)\
\-\ complying\\:\\ 0\\.06374481404542248\ \(0\)\
\-\ hydroxyurea\\:\\ 0\\.06374481404542248\ \(0\)\
\-\ phlebotomy\\:\\ 0\\.06374481404542248\ \(0\)\
\-\ neuropsychological\\:\\ 0\\.06374481404542248\ \(0\)\
\-\ 19\\:\\ 0\\.0631311550819148\ \(0\)\
\-\ considered\\:\\ 0\\.06212045468251975\ \(0\)\
\-\ narrowing\\:\\ 0\\.06179917007665341\ \(0\)\
\-\ were\\:\\ 0\\.06164003133085998\ \(0\)\
\-\ complications\\:\\ 0\\.06105694620197953\ \(0\)\
\-\ 303\\:\\ 0\\.060911572909661586\ \(0\)\
\-\ executive\\:\\ 0\\.060911572909661586\ \(0\)\
\-\ diamox\\:\\ 0\\.060911572909661586\ \(0\)\
\-\ candidacy\\:\\ 0\\.060911572909661586\ \(0\)\
\-\ tranfusions\\:\\ 0\\.060911572909661586\ \(0\)\
\-\ are\\:\\ 0\\.06050022538831289\ \(0\)\
\-\ had\\:\\ 0\\.05957914935785559\ \(0\)\
\-\ in\\:\\ 0\\.0594952430055623\ \(0\)\
\-\ dyscrasias\\:\\ 0\\.05890135633271781\ \(0\)\
\-\ recurrance\\:\\ 0\\.05890135633271781\ \(0\)\
\-\ reported\\:\\ 0\\.05741816606249681\ \(0\)\
\-\ managment\\:\\ 0\\.05734211121859929\ \(0\)\
\-\ trifurcation\\:\\ 0\\.05734211121859929\ \(0\)\
\-\ risk\\:\\ 0\\.05696141740879733\ \(0\)\
\-\ identified\\:\\ 0\\.05651912527886601\ \(0\)\
\-\ electrophoresis\\:\\ 0\\.054990966908587825\ \(0\)\
\-\ supraclinoid\\:\\ 0\\.054990966908587825\ \(0\)\
\-\ implying\\:\\ 0\\.054990966908587825\ \(0\)\
\-\ compliant\\:\\ 0\\.054990966908587825\ \(0\)\
\-\ origins\\:\\ 0\\.05405789862001314\ \(0\)\
\-\ reflecting\\:\\ 0\\.05405789862001314\ \(0\)\
\-\ tias\\:\\ 0\\.05405789862001314\ \(0\)\
\-\ collateralization\\:\\ 0\\.053234874061196015\ \(0\)\
\-\ hope\\:\\ 0\\.053234874061196015\ \(0\)\
\-\ pial\\:\\ 0\\.05249865350589462\ \(0\)\
\-\ a1\\:\\ 0\\.05249865350589462\ \(0\)\
\-\ m1\\:\\ 0\\.05249865350589462\ \(0\)\
\-\ organizing\\:\\ 0\\.05249865350589462\ \(0\)\
\-\ challenge\\:\\ 0\\.05249865350589462\ \(0\)\
\-\ any\\:\\ 0\\.05152144357776544\ \(0\)\
\-\ while\\:\\ 0\\.05152144357776544\ \(0\)\
\-\ evolving\\:\\ 0\\.05066534846489797\ \(0\)\
\-\ peduncle\\:\\ 0\\.05066534846489797\ \(0\)\
\-\ age\\:\\ 0\\.050049002467162644\ \(0\)\
\-\ intracerebral\\:\\ 0\\.04921444090730846\ \(0\)\
\-\ attenuated\\:\\ 0\\.048790818334279444\ \(0\)\
\-\ prevention\\:\\ 0\\.048790818334279444\ \(0\)\
\-\ why\\:\\ 0\\.04839141634849134\ \(0\)\
\-\ for\\:\\ 0\\.048325037694287434\ \(0\)\
\-\ dysarthria\\:\\ 0\\.04801361448012843\ \(0\)\
\-\ static\\:\\ 0\\.04765519579318994\ \(0\)\
\-\ manifest\\:\\ 0\\.04765519579318994\ \(0\)\
\-\ utilizing\\:\\ 0\\.04765519579318994\ \(0\)\
\-\ anastomosis\\:\\ 0\\.047314268060122254\ \(0\)\
\-\ time\\:\\ 0\\.04725205175390824\ \(0\)\
\-\ transfusion\\:\\ 0\\.04698920329055925\ \(0\)\
\-\ cva\\:\\ 0\\.04698920329055925\ \(0\)\
\-\ authors\\:\\ 0\\.04667859071316538\ \(0\)\
\-\ been\\:\\ 0\\.04644577237972227\ \(0\)\
\-\ omental\\:\\ 0\\.04638119977154756\ \(0\)\
\-\ living\\:\\ 0\\.04638119977154756\ \(0\)\
\-\ if\\:\\ 0\\.046319298531520954\ \(0\)\
\-\ apparently\\:\\ 0\\.0458218907521933\ \(0\)\
\-\ planning\\:\\ 0\\.045304051483178474\ \(0\)\
\-\ who\\:\\ 0\\.04509455094355618\ \(0\)\
\-\ these\\:\\ 0\\.045017868913880044\ \(0\)\
\-\ warranted\\:\\ 0\\.04459283142833081\ \(0\)\
\-\ anterior\\:\\ 0\\.04451098709359537\ \(0\)\
\-\ functioning\\:\\ 0\\.044155962154798355\ \(0\)\
\-\ hemiparesis\\:\\ 0\\.04394736062157477\ \(0\)\
\-\ activities\\:\\ 0\\.04374480636905996\ \(0\)\
\-\ symptoms\\:\\ 0\\.04361826572212025\ \(0\)\
\-\ bifurcation\\:\\ 0\\.042988649616432395\ \(0\)\
\-\ fully\\:\\ 0\\.042988649616432395\ \(0\)\
\-\ plt\\:\\ 0\\.042811738080485266\ \(0\)\
\-\ confusion\\:\\ 0\\.042639195180143315\ \(0\)\
\-\ reasons\\:\\ 0\\.04230638788078774\ \(0\)\
\-\ noted\\:\\ 0\\.04226742494852182\ \(0\)\
\-\ hemoglobin\\:\\ 0\\.042145745577854575\ \(0\)\
\-\ mentioned\\:\\ 0\\.042145745577854575\ \(0\)\
\-\ directed\\:\\ 0\\.04198871352166814\ \(0\)\
\-\ can\\:\\ 0\\.04183452815235609\ \(0\)\
\-\ present\\:\\ 0\\.04090691898469665\ \(0\)\
\-\ ages\\:\\ 0\\.04071471750002577\ \(0\)\
\-\ effective\\:\\ 0\\.04071471750002577\ \(0\)\
\-\ segments\\:\\ 0\\.0404605937704738\ \(0\)\
\-\ exam\\:\\ 0\\.040131085669269775\ \(0\)\
\-\ may\\:\\ 0\\.04011761553343586\ \(0\)\
\-\ supply\\:\\ 0\\.040095938909607005\ \(0\)\
\-\ future\\:\\ 0\\.03997849694472437\ \(0\)\
\-\ perfusion\\:\\ 0\\.03997849694472437\ \(0\)\
\-\ various\\:\\ 0\\.03986299625848261\ \(0\)\
\-\ compatible\\:\\ 0\\.03986299625848261\ \(0\)\
\-\ have\\:\\ 0\\.03982451057955389\ \(0\)\
\-\ diminished\\:\\ 0\\.03952752548189911\ \(0\)\
\-\ branches\\:\\ 0\\.03952752548189911\ \(0\)\
\-\ procedures\\:\\ 0\\.039103902908870086\ \(0\)\
\-\ patient\\:\\ 0\\.03889336881153967\ \(0\)\
\-\ nor\\:\\ 0\\.03880223164097885\ \(0\)\
\-\ hgb\\:\\ 0\\.03870450092308199\ \(0\)\
\-\ well\\:\\ 0\\.038600814866528534\ \(0\)\
\-\ superficial\\:\\ 0\\.03851304696269162\ \(0\)\
\-\ treatment\\:\\ 0\\.037974863992336294\ \(0\)\
\-\ portions\\:\\ 0\\.037881476364264866\ \(0\)\
\-\ hct\\:\\ 0\\.03779573746743863\ \(0\)\
\-\ daily\\:\\ 0\\.03779573746743863\ \(0\)\
\-\ basilar\\:\\ 0\\.03771103785557347\ \(0\)\
\-\ better\\:\\ 0\\.0376273526347129\ \(0\)\
\-\ ganglia\\:\\ 0\\.03746293016808307\ \(0\)\
\-\ cns\\:\\ 0\\.037223330726493455\ \(0\)\
\-\ stroke\\:\\ 0\\.037068043615358634\ \(0\)\
\-\ anticoagulation\\:\\ 0\\.03699167528775603\ \(0\)\
\-\ assess\\:\\ 0\\.036841397830861024\ \(0\)\
\-\ within\\:\\ 0\\.036716571703154996\ \(0\)\
\-\ develop\\:\\ 0\\.036694284346138216\ \(0\)\
\-\ number\\:\\ 0\\.036694284346138216\ \(0\)\
\-\ 41\\:\\ 0\\.03655020434634382\ \(0\)\
\-\ residual\\:\\ 0\\.03627066177310919\ \(0\)\
\-\ higher\\:\\ 0\\.036202489208737726\ \(0\)\
\-\ again\\:\\ 0\\.03555502336059115\ \(0\)\
\-\ prognosis\\:\\ 0\\.03507705024840069\ \(0\)\
\-\ volume\\:\\ 0\\.03501953854577793\ \(0\)\
\-\ that\\:\\ 0\\.03459548847537643\ \(0\)\
\-\ cavernous\\:\\ 0\\.03457573021266543\ \(0\)\
\-\ problems\\:\\ 0\\.03457573021266543\ \(0\)\
\-\ decrease\\:\\ 0\\.03426044519616541\ \(0\)\
\-\ those\\:\\ 0\\.03410798171315439\ \(0\)\
\-\ basal\\:\\ 0\\.03410798171315439\ \(0\)\
\-\ poor\\:\\ 0\\.03362253430837991\ \(0\)\
\-\ even\\:\\ 0\\.03352936449576504\ \(0\)\
\-\ cbc\\:\\ 0\\.03325708463065245\ \(0\)\
\-\ lobes\\:\\ 0\\.03325708463065245\ \(0\)\
\-\ marrow\\:\\ 0\\.033124822655075915\ \(0\)\
\-\ development\\:\\ 0\\.03295227975473396\ \(0\)\
\-\ neurological\\:\\ 0\\.03274242517166879\ \(0\)\
\-\ suspected\\:\\ 0\\.03266021678319729\ \(0\)\
\-\ normal\\:\\ 0\\.03254913966741402\ \(0\)\
\-\ thrombosis\\:\\ 0\\.03249864582953209\ \(0\)\
\-\ screening\\:\\ 0\\.03237987301378877\ \(0\)\
\-\ be\\:\\ 0\\.032339215191337846\ \(0\)\
\-\ addition\\:\\ 0\\.032263085352237576\ \(0\)\
\-\ external\\:\\ 0\\.03222458590265396\ \(0\)\
\-\ compared\\:\\ 0\\.03222458590265396\ \(0\)\
\-\ procedure\\:\\ 0\\.03177841528675261\ \(0\)\
\-\ from\\:\\ 0\\.03166140248372965\ \(0\)\
\-\ arteries\\:\\ 0\\.03163580559362811\ \(0\)\
\-\ limits\\:\\ 0\\.03149604828646947\ \(0\)\
\-\ not\\:\\ 0\\.03147155793116371\ \(0\)\
\-\ appear\\:\\ 0\\.03139303464061544\ \(0\)\
\-\ prominent\\:\\ 0\\.03139303464061544\ \(0\)\
\-\ pathology\\:\\ 0\\.03129151761407927\ \(0\)\
\-\ vessels\\:\\ 0\\.030931419409665355\ \(0\)\
\-\ symptomatic\\:\\ 0\\.03065000020625351\ \(0\)\
\-\ temporal\\:\\ 0\\.03061941970920531\ \(0\)\
\-\ currently\\:\\ 0\\.03061941970920531\ \(0\)\
\-\ hypertension\\:\\ 0\\.030498418721656144\ \(0\)\
\-\ an\\:\\ 0\\.030484658726586237\ \(0\)\
\-\ worsening\\:\\ 0\\.03043869500403783\ \(0\)\
\-\ unknown\\:\\ 0\\.030204777515799298\ \(0\)\
\-\ note\\:\\ 0\\.03000633242683888\ \(0\)\
\-\ used\\:\\ 0\\.029840610056489764\ \(0\)\
\-\ appears\\:\\ 0\\.029189521859025205\ \(0\)\
\-\ grade\\:\\ 0\\.028662807150708576\ \(0\)\
\-\ wbc\\:\\ 0\\.028173027385842236\ \(0\)\
\-\ effect\\:\\ 0\\.027961264743122133\ \(0\)\
\-\ being\\:\\ 0\\.02777601474267372\ \(0\)\
\-\ new\\:\\ 0\\.027575782348436752\ \(0\)\
\-\ now\\:\\ 0\\.027361957718603058\ \(0\)\
\-\ hemorrhage\\:\\ 0\\.026687268721479758\ \(0\)\
\-\ flow\\:\\ 0\\.026549576927910767\ \(0\)\
\-\ right\\:\\ 0\\.026430477029744572\ \(0\)\
\-\ vascular\\:\\ 0\\.02631495811660014\ \(0\)\
\-\ should\\:\\ 0\\.026008646061912246\ \(0\)\
\-\ further\\:\\ 0\\.02596148525911636\ \(0\)\
\-\ between\\:\\ 0\\.025899095269435603\ \(0\)\
\-\ found\\:\\ 0\\.02579123551607427\ \(0\)\
\-\ frontal\\:\\ 0\\.025654961008951465\ \(0\)\
\-\ severe\\:\\ 0\\.02523310276680491\ \(0\)\
\-\ years\\:\\ 0\\.024433645287402855\ \(0\)\
\-\ all\\:\\ 0\\.02372770704351675\ \(0\)\
\-\ scan\\:\\ 0\\.023648494167768656\ \(0\)\
\-\ secondary\\:\\ 0\\.02362602587695412\ \(0\)\
\-\ presented\\:\\ 0\\.023244092981321695\ \(0\)\
\-\ distal\\:\\ 0\\.023159649265760477\ \(0\)\
\-\ due\\:\\ 0\\.02291227361246726\ \(0\)\
\-\ low\\:\\ 0\\.022871882561142934\ \(0\)\
\-\ than\\:\\ 0\\.022595499489425033\ \(0\)\
\-\ mild\\:\\ 0\\.022595499489425033\ \(0\)\
\-\ signal\\:\\ 0\\.022595499489425033\ \(0\)\
\-\ prior\\:\\ 0\\.022301738801117486\ \(0\)\
\-\ more\\:\\ 0\\.021887402119717982\ \(0\)\
\-\ bone\\:\\ 0\\.02174885716141879\ \(0\)\
\-\ physical\\:\\ 0\\.02161300583661351\ \(0\)\
\-\ increased\\:\\ 0\\.021554391440243858\ \(0\)\
\-\ follow\\:\\ 0\\.02148800013392988\ \(0\)\
\-\ without\\:\\ 0\\.021024650222477126\ \(0\)\
\-\ posterior\\:\\ 0\\.020611948671347434\ \(0\)\
\-\ mri\\:\\ 0\\.02046058609411127\ \(0\)\
\-\ up\\:\\ 0\\.01971723893704693\ \(0\)\
\-\ findings\\:\\ 0\\.019672507712542746\ \(0\)\
\-\ surgical\\:\\ 0\\.019373259169677443\ \(0\)\
\-\ presents\\:\\ 0\\.019174716437627404\ \(0\)\
\-\ also\\:\\ 0\\.018749000610074902\ \(0\)\
\-\ which\\:\\ 0\\.01812473759266543\ \(0\)\
\-\ was\\:\\ 0\\.013891603869363002\ \(0\)\
\-\ no\\:\\ 0\\.012962017731865942\ \(0\)\
\-\ year\\:\\ 0\\.012284066548826637\ \(0\)\
\-\ on\\:\\ 0\\.012038403524607251\ \(0\)\
\-\ old\\:\\ 0\\.011796956122035362\ \(0\)\
